Jan 18, 2022
Cellular Biomedicine Group Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for Bi-Specific CAR-T Cell Therapy C-CAR039 for the Treatment of Relapsed/Refractory Large B-cell Lymphomas
Dec 16, 2021
Dec 16, 2021
U.S. FDA Grants Cellular Biomedicine Group Clearance of the IND Application for C-CAR039, a Bi-Specific CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphomas
Mar 15, 2021
FDA Grants Clearance of IND Application to TrueBinding, Inc. of TB006 for Reducing Severity of Underlying Diseases in COVID-19 Patients
Dec 02, 2020
FDA Grants Clearance of IND Application to TransThera Biosciences of TT-00420 for the Treatment of Cholangiocarcinoma
Jul 13, 2020
GeneQuantum Healthcare Announces First Patient Dosed in Phase I Clinical Trial of GQ1001
Jul 01, 2020
ABM Therapeutics Announces First Patient Dosed in First-In-Human Trial of ABM-1310 in the U.S.
Jun 19, 2020
FDA Grants GeneQuantum Healthcare Clearance to Proceed with Clinical Development of Lead Candidate, GQ1001, in the U.S.
Dec 18, 2019
FDA Grants TransThera Biosciences Clearance to Proceed with Clinical Development of TT-00920 in the U.S.
Dec 10, 2019
FDA Grants ABM Therapeutics Clearance to Proceed with Clinical Development of ABM-1310 in the U.S.
Nov 06, 2019
FDA Grants Orphan Drug Designation to TT-00420 for the Treatment of Cholangiocarcinoma
Oct 31, 2019
Advance Communications on Regulatory Sciences and Promote Global Interactions Among Regulatory Agencies
Jan 08, 2019
CRC Oncology Announces First Patient Dosed in Phase I Clinical Trial of TransThera Biosciences’ TT-00420 in the U.S.
Oct 29, 2018
CBMG Open GMP Doors to International Attendees.
Oct 15, 2018
CRC Oncology Announces the Opening of New Office in Beijing, Strengthening Global Presence in China.
Sep 28, 2018
FDA Grants TransThera Biosciences Approval to Proceed with the Clinical Development of TT-00420 in the U.S.
Jun 5, 2018
CRC Oncology Selects Medrio eClinical with Eye Toward New Business in China.